Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the drug market for the treatment of colorectal cancer will experience significant growth of 16.6% annually through 2009.

The new Pharmacor report entitled Colorectal Cancer finds that the extension of Roche's Xeloda (capecitabine), Sanofi-Aventis's Eloxatin/Eloxatine (oxaliplatin), and Yakult's Elplat (oxaliplatin) into adjuvant therapy regimens will fuel market growth for cytotoxic agents in the treatment of operable colorectal cancer. The report also forecasts healthy, but more modest market growth of 6.6% annually during the second half of the study period, 2009 to 2014.

"More aggressive adjuvant treatment of operable colorectal cancer will drive the sales of Xeloda, Eloxatin/Eloxatine, and Elplat, all of which are currently used to treat inoperable metastatic colorectal cancer," said Joanne Graham, Ph.D., analyst at Decision Resources, Inc. "Additionally, recent European approvals of Genentech/Roche's Avastin (bevacizumab) and ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux (cetuximab) will add to the already thriving market in the United States for biologicals that provide additional treatment options and extend overall survival for inoperable metastatic colorectal cancer."

About Colorectal Cancer

Colorectal cancer is the third most common form of cancer worldwide. Despite significant progress in its treatment over the past decade, colorectal cancer remains the second-leading cause of malignancy-related death in the United States.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Medicare Prescription Drug Plan Competition Above Average in South Carolina, According to HealthLeaders-InterStudy

View Now